Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Cha

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
The Oncologist|March 20, 2023
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study PlatformAndrew H Ko, Kyu-Pyo Kim, Jens T Siveke, et al.
Journal for Immunotherapy of Cancer|June 27, 2017
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31<sup>st</sup>Annual Meeting of the Society for Immunotherapy of Cancer, 2016Prasad S Adusumilli, Edward Cha, Mark Cornfeld, et al.
Cell Reports. Medicine|November 29, 2025
Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapyYulei Wang, Yinghui Guan, Alexander R Abbas, et al.
Lancet (London, England)|October 23, 2023
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trialShukui Qin, Minshan Chen, Ann-Lii Cheng, et al.
Journal for Immunotherapy of Cancer|April 3, 2020
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance TaskforceHarriet M Kluger, Hussein A Tawbi, Maria L Ascierto, et al.
Cancer Immunology Research|October 18, 2017
A Blueprint to Advance Colorectal Cancer ImmunotherapiesDung T Le, Vanessa M Hubbard-Lucey, Michael A Morse, et al.
Gut|August 26, 2021
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibitionRaghav Sundar, Kie-Kyon Huang, Vikrant Kumar, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
The Oncologist|March 20, 2023
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study PlatformAndrew H Ko, Kyu-Pyo Kim, Jens T Siveke, et al.
Journal for Immunotherapy of Cancer|June 27, 2017
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31<sup>st</sup>Annual Meeting of the Society for Immunotherapy of Cancer, 2016Prasad S Adusumilli, Edward Cha, Mark Cornfeld, et al.
Cell Reports. Medicine|November 29, 2025
Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapyYulei Wang, Yinghui Guan, Alexander R Abbas, et al.
Lancet (London, England)|October 23, 2023
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trialShukui Qin, Minshan Chen, Ann-Lii Cheng, et al.
Journal for Immunotherapy of Cancer|April 3, 2020
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance TaskforceHarriet M Kluger, Hussein A Tawbi, Maria L Ascierto, et al.
Cancer Immunology Research|October 18, 2017
A Blueprint to Advance Colorectal Cancer ImmunotherapiesDung T Le, Vanessa M Hubbard-Lucey, Michael A Morse, et al.
Gut|August 26, 2021
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibitionRaghav Sundar, Kie-Kyon Huang, Vikrant Kumar, et al.
Pageof 3